drugset
drugset / Trial / NCT05633862

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

NCT05633862 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.

Timeline

Start
2023-01-13
Primary completion
2023-03-16
Completion
2023-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule 9 mg Oral
Subject Nerandomilast Small molecule 18 mg Oral

Indications

No indication recorded.